论文部分内容阅读
目的:评价三种植物来源抗肿瘤药物在食管癌化疗中的经济效益和临床作用特点。方法:采用回溯法筛选了111例食管癌病例,分成3组,分别为Ⅰ组PVB方案(长春地辛VDS+博莱霉素BLM+顺铂DDP);Ⅱ组TD方案(紫杉醇TAXOL+顺铂DDP);Ⅲ组PEF方案(足叶乙甙VP-16+氟尿嘧啶5-FU+顺铂DDP)。运用药物流行学的疗效比较和药物经济学的成本—效果分析方法进行研究。结果:3组疗效分别为55.56%,47.36%,43.24%。成本效果比分别为380.13元,423.45元,379.46元。结论:PVB方案具有较好的药物经济学意义。
Objective: To evaluate the economic benefits and clinical features of three plant-derived antitumor drugs in esophageal cancer chemotherapy. Methods: 111 cases of esophageal cancer were screened by retrospective method and divided into 3 groups: group Ⅰ PVB (vindesine VDS + bleomycin BLM + cisplatin DDP); group Ⅱ TD (paclitaxel TAXOL + cisplatin DDP); group Ⅱ Group Ⅲ PEF program (etoposide VP-16 + fluorouracil 5-FU + cisplatin DDP). Using the comparison of the efficacy of the pharmaco-epidemiology and the cost-effectiveness analysis method of pharmacoeconomics. Results: The three groups were 55.56%, 47.36% and 43.24% respectively. Cost-effectiveness ratio was 380.13 yuan, 423.45 yuan, 379.46 yuan. Conclusion: PVB program has good pharmacological significance.